Biology and potential strategies for the treatment of G(M2) gangliosidoses

Molecular Medicine Today

Volumn 4, Issue 4, 1998, Pages 158-165

  Chavany, Christine ^a   Jendoubi, Moncef ^a  

^a GMBB/NHGRI Building 49   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; MIGLUSTAT;

AMINO ACID SUBSTITUTION; ANIMAL MODEL; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CONFERENCE PAPER; ENZYME SUBSTRATE COMPLEX; ENZYME THERAPY; FAILURE TO THRIVE; GENE THERAPY; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PATHOGENESIS; POINT MUTATION; PSYCHOMOTOR DISORDER; SANDHOFF DISEASE; TAY SACHS DISEASE;

1-DEOXYNOJIRIMYCIN; ADOLESCENT; ADULT; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASE; BONE MARROW TRANSPLANTATION; CATS; CELL TRANSPLANTATION; CHILD; DISEASE MODELS, ANIMAL; DOGS; G(M2) GANGLIOSIDE; GENE THERAPY; GENETIC VECTORS; GLYCOLIPIDS; HIV; HUMANS; INFANT; LYSOSOMES; MICE; MICE, KNOCKOUT; NEURONS; PHENOTYPE; POINT MUTATION; RATS; SANDHOFF DISEASE; SWINE; TAY-SACHS DISEASE; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA;

EID: 0031969246     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01227-1     Document Type: Conference Paper

References (36)

1. M2 gangliosidosis. Biochim. Biophys. Acta. 1096:1991;87-94.
2. M2 ganglioside and hexosaminidase A. Biochim. Biophys. Acta. 1340:1997;45-52.
3. Sango K.et al. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nat. Genet. 14:1996;348-352.
4. M2 gangliosidoses, in The Metabolic Basis of Inherited Disease (Scriver, C.V., Beaudet, A.L., Sly, W.S. and Valle, D., eds), pp. 1807-1839, McGraw-Hill.
5. M2 gangliosidoses, in The Metabolic and Molecular Basis of Inherited Disease (Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D., eds), pp. 2839-2879, McGraw-Hill.
6. Natowicz M.R., Prence E.M. Heterozygote screening for Tay-Sachs disease: past successes and future challenges. Curr. Opin. Pediatr. 8:1996;625-629.
7. M2 gangliosidosis (Sandhoff disease) homozygosity for the Ile207→Val substitution is not associated with a clinical or biochemical phenotype. Biochim. Biophys. Acta. 1317:1996;127-133.
8. Frederico A.et al. The clinical aspects of adult hexosaminidase deficiencies. Dev. Neurosci. 13:1991;280-287.
9. M2-gangliosidosis (Sandhoff disease). Am. J. Pathol. 144:1994;1109-1118.
10. Siegel D.A., Walkley S.U. Growth of ectopic dendrites on cortical pyramidal neurons in neuronal storage diseases correlates with abnormal accumulation of GM2 ganglioside. J. Neurochem. 62:1994;1852-1862.
11. Cohen-Tannoudji M.et al. Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease. Mamm. Genome. 6:1995;844-849.
12. Yamanaka S.et al. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9975-9979.
13. Phaneuf D.et al. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 5:1996;1-14.
14. Sango K.et al. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat. Genet. 11:1995;170-176.
15. M2 activator deficiency manifest cerebellar pathology and motor impairment. Proc. Natl. Acad. Sci. U. S. A. 94:1997;8138-8143.
16. M2 mobilization. Acta Neuropathol. 50:1980;9-17.
17. Neuwelt E.A.et al. Delivery of active hexosaminidase across the blood-brain barrier in rats. Neurology. 34:1984;1012-1019.
18. Platt F.M.et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 276:1997;428-431.
19. Walkley S.U., Dobrenis K. Bone marrow transplantation for lysosomal diseases. Lancet. 345:1995;1382-1383.
20. Birkenmeier E.H.et al. Increased lifespan and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood. 78:1991;3081-3092.
21. Blömer U.et al. Applications of gene therapy to the CNS. Hum. Mol. Genet. 5:1996;1397-1404.
22. Maréchal V., Naffakh N., Danos O., Heard J.M. Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells. Blood. 82:1993;1358-1365.
23. Wolfe J.H.et al. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature. 360:1992;749-753.
24. Moullier P., Bohl D., Heard J.M., Danos O. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblast. Nat. Genet. 4:1993;154-159.
25. Flink D.J.et al. Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system. Clin. Neurosci. 3:1996;284-291.
26. Sabate O.et al. Adenovirus for neurodegenerative diseases: in vivo strategies and ex vivo gene therapy using human neural progenitors. Clin. Neurosci. 3:1996;317-321.
27. Wolfe J.H., Deshmane S.L., Fraser N.W. Herpes virus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice. Nat. Genet. 1:1992;379-384.
28. Ohashi T.et al. Adenovirus-mediated gene transfer and expression of beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc. Natl. Acad. Sci. U. S. A. 94:1997;1287-1292.
29. Akli S.et al. Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adenoviral vector-mediated gene transfer. Gene Ther. 3:1996;769-774.
30. Aebischer P.et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2:1996;696-699.
31. Pizzorusso T.et al. Transplant of polymer-encapsulated cells genetically engineered to release nerve growth factor allows a normal functional development of the visual cortex in dark-reared rats. Neuroscience. 80:1997;307-311.
32. Taylor R.M., Wolfe J.H. Decreased lysosomal storage in the adult MPS VIII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat. Med. 3:1997;771-774.
33. Snyder E.Y., Wolfe J.H. Central nervous system cell transplantation: a novel therapy for storage diseases? Curr. Opin. Neurol. 9:1996;126-136.
34. Snyder E.Y., Taylor R.M., Wolfe J.H. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature. 374:1995;367-370.
35. Acorazza H.D., Flax J.D., Snyder E.Y., Jendoubi M. Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat. Med. 2:1996;424-429.
36. Sabate O.et al. Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses. Nat. Genet. 9:1995;256-260.